ASX:COHMedical Equipment
Did Cochlear’s (ASX:COH) Guidance Cut Quietly Recast the Premium Medtech Growth Story?
Cochlear Limited recently downgraded its 2026 earnings guidance, a move that has already influenced sentiment toward premium medical device companies across the ASX healthcare sector.
This shift comes as the global ear health market, worth about US$10.12 billion in 2025, is projected to expand meaningfully over the coming decade, underscoring the contrast between long-term industry growth and near-term earnings uncertainty for Cochlear.
With Cochlear’s guidance downgrade resetting...